decisionhealth Newsletters, Part B News - 2025 Issue 2 (February)
OIG offers advisory opinion on pharma coverage
Subscribe or sign in to view the full article.
Article Overview
This article covers an HHS Office of Inspector General advisory opinion addressing a proposed pharmaceutical access program for financially needy patients without adequate coverage. It is relevant to compliance, healthcare legal, and pharmacy stakeholders who monitor fraud-and-abuse guidance, especially OIG interpretations of federal anti-kickback and beneficiary inducement rules.
Why This Topic Matters
It helps readers understand how OIG evaluates patient assistance arrangements and why coverage, eligibility, and compliance review matter when access programs intersect with federal enforcement concerns.
What You Will Learn
- The general purpose of the OIG advisory opinion
- How a free-access patient program is described at a high level
- The types of federal compliance issues reviewed in the opinion
- Why the article may matter to pharmacy, compliance, and legal professionals
Who Should Read This
- Healthcare compliance professionals
- Healthcare attorneys
- Pharmacy program administrators
- Revenue cycle and reimbursement professionals
- Pharmaceutical manufacturer compliance teams
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com